drugset / Trial / NCT00858325

Pharmacokinetic Study of Daptomycin in Healthy Chinese Subjects Living in China

NCT00858325

Phase 1 Completed 24 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to characterise the pharmacokinetics and dose proportionality of daptomycin after single and multiple (once daily) 4mg/kg and 6 mg/kg doses of daptomycin in healthy Chinese volunteers.

Timeline

Start
2009-02
Primary completion
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Daptomycin Other / unclassified 4 mg/kg Intravenous
Subject Daptomycin Other / unclassified 6 mg/kg Intravenous

Indications

No indication recorded.